

Amendments to the Claims:

Please amend that the claims as indicated, where underlining OOO refers to added text and strikethrough ~~OOO~~ refers to deleted text.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) An isolated antibody comprising an Fc region and three or more antigen binding sites amino-terminal to the Fc region.
2. (Original) The antibody of claim 1 comprising four antigen binding sites.
3. (Cancelled)
4. (Original) The antibody of claim 1 comprising a polypeptide chain, wherein the polypeptide chain comprises two or more variable domains.
5. (Original) The antibody of claim 4 wherein the polypeptide chain comprises VD1-(X1)_n-VD2-(X2)_n-Fc, wherein VD1 is a first variable domain, VD2 is a second variable domain, Fc is one polypeptide chain of an Fc region, X1 and X2 represent an amino acid or polypeptide, and n is 0 or 1.
6. (Original) The antibody of claim 5 comprising two or more polypeptide chains, each comprising VD1-(X1)_n-VD2-(X2)_n-Fc.
7. (Original) The antibody of claim 1 comprising at least one polypeptide chain with the formula:
 - (a) VH-CH1-flexible linker-VH-CH1-Fc region chain; or
 - (b) VH-CH1-VH-CH1-Fc region chain.
8. (Original) The antibody of claim 1 comprising at least two light chain variable domain polypeptides.
9. (Original) The antibody of claim 8 wherein the light chain variable domain polypeptides further comprise a CL domain.
10. (Cancelled)
11. (Previously presented) The antibody of claim 7 wherein the flexible linker comprises the peptide gly-ser-gly-ser (SEQ ID NO:10).

12. (Original) The antibody of claim 1 which is internalized faster than a bivalent antibody by a cell expressing an antigen to which the antibodies bind.
 13. (Original) The antibody of claim 1 which is an agonist antibody.
 14. (Original) The antibody of claim 1 which induces apoptosis.
 15. (Original) The antibody of claim 1 wherein the three or more antigen binding sites all bind the same antigen.
 16. (Cancelled)
 17. - 20. (Cancelled)
 21. (Previously presented) The antibody of claim 1 which binds a DR5 receptor.
 22. - 24. (Cancelled)
 25. (Original) The antibody of claim 21 which is an agonist antibody.
 26. (Original) The antibody of claim 21 which induces apoptosis.
 27. - 32. (Cancelled)
 33. (Currently amended) An isolated antibody comprising three or more antigen binding sites, wherein the antibody is not a native sequence IgM or IgA antibody and is capable of binding a receptor in the Tumor Necrosis Factor (TNF) receptor superfamily.
- Please cancel claim 34 without prejudice to later prosecution.
34. (Cancelled herewith) ~~The antibody of claim 33 which is not a native sequence IgM or IgA antibody.~~
 35. (Original) The antibody of claim 33 which has only one Fc region or lacks an Fc region.
 36. (Original) The antibody of claim 33 which comprises a polypeptide chain, wherein the polypeptide chain comprises two or more variable domains.
 37. (Original) The antibody of claim 33 which comprises four antigen binding sites each capable of binding the DR5 receptor.
 38. - 40. (Cancelled)
 41. (Original) The antibody of claim 33 which is an agonist antibody.
 42. (Original) The antibody of claim 33 which induces apoptosis.
 43. - 56. (Cancelled)
 57. (Previously presented) A polypeptide chain comprising:
 - (a) VH-CH1-flexible linker-VH-CH1-dimerization domain; or

VH-CH1-VH-CH1-dimerization domain; and
wherein the dimerization domain comprises an Fc region.

58. (Original) An isolated antibody comprising the polypeptide chain of claim 57.
59. (Original) The antibody of claim 58 further comprising two or more light chain variable domain polypeptides.
60. (Original) The antibody of claim 59 wherein the light chain variable domain polypeptides comprise VL-CL.
61. (Currently amended) An isolated antibody comprising a dimerization domain and three or more antigen binding sites amino-terminal thereto, wherein the antibody is not a native sequence IgM or IgA antibody.
62. (Original) The antibody of claim 61 wherein the dimerization domain is selected from the group consisting of a hinge region, an Fc region, a CH3 domain, and a CH4 domain.
63. (Original) The antibody of claim 62 wherein the dimerization domain is a hinge region.
64. (The antibody of claim 63 wherein the dimerization domain further comprises a leucine zipper.
65. (Original) The antibody of claim 63 comprising a polypeptide chain comprising the formula:
 - (a) VH-CH1-flexible linker-VH-CH1-hinge region; or
 - (b) VH-CH1-VH-CH1-hinge region.
66. (Currently amended) A polypeptide chain comprising three or more heavy chain or light chain variable domains, wherein each of the variable domains is able to combine with three or more light chain or heavy chain variable domain polypeptides to form three or more antigen binding sites, each directed against the same antigen and wherein the antibody is not a native sequence IgM or IgA antibody.
67. (Cancelled)
68. (Original) The polypeptide chain of claim 66 which comprises four heavy chain variable domains which are able to combine with four light chain variable domain polypeptides to form four antigen binding sites directed against the same antigen.
69. (Previously presented) The polypeptide chain of claim 66 wherein the antigen is a DR5 receptor.

70-73. (Cancelled)

74. (Previously presented) The polypeptide chain of claim 68 comprising the formula:

(a) VH-CH1-flexible linker-VH-CH1-flexible linker-VH-CH1;

(b) VH-CH1-flexible linker-VH-CH1-flexible linker-VH-CH1-flexible linker-VH-CH1; or

(c) (VH-CH1)_n, wherein n is three or four.

75. (Original) An isolated antibody comprising the polypeptide chain of claim 66.

76. (Original) The isolated antibody of claim 75 further comprising the three or more light chain or heavy chain variable domain polypeptides.

77. (Original) The isolated antibody of claim 76 comprising three or more light chain variable domain polypeptides, each comprising VL-CL.

78. (Original) The isolated antibody of claim 77 comprising four light chain variable domain polypeptides, each comprising VL-CL.

79. (Cancelled)

80. (Original) An immunoconjugate comprising the antibody of claim 75 conjugated with a cytotoxic agent.

81-93. (Cancelled)